Live
BioPharma DivecAMPfield lands $180M to build gut disease drugEndpoints NewsNovo Nordisk expands in China and Czech; Cellares boosts Series D by $50MBioPharma DiveBiogen adds more immune drugs in $1B buyout of secretive startup RaytheraPromega BlogWhat Happens When You Delay an Ebola Vaccine Booster by 18 Months?FierceBiotechcAMPfield harvests $180M series A to advance oral IBD drug licensed from NewsoaraEndpoints NewsIRA's Medicare out-of-pocket cap increased access to drugs, study findsEndpoints NewsPrepping for peptidesBioPharma DivePfizer CFO to step down; Denali sells a regulatory fast-passEndpoints NewsPfizer CFO to depart; GSK wins approval for UTI drugEndpoints NewsRA, Forbion and Sanofi Ventures appear to back new eye drug from KoreaEndpoints NewsNovocure’s electric fields therapy fails key glioblastoma studyBioWorldShanghai Pharmaceuticals discovers new IL-17A inhibitors
BioPharma Dive Jan 22, 2026

Investors load Corxel with $287M for a ‘differentiated’ obesity pill

Investors load Corxel with $287M for a ‘differentiated’ obesity pill

Original
Body unavailable. Use the original source.